NeoVirTech (NVT) is one of the leading virus imaging and antiviral discovery company in Europe. The company has been highlighted in the Top10 drug discovery companies, Europe, 2019 by the PharmaTechOutlook Magazine. NVT has developed a breakthrough technology to directly visualize and quantify in real time virus/viral vector infection and replication in living cells, from high resolution to high content imaging. At NeoVirTech, we believe everyone can have access to state-of-the-art virology techniques. We are focusing our activities on antiviral discovery, study of oncolytic and gene therapy products and quantification of disinfection procedures (physical, chemical, radiative) on a strong collection of pathogenous viruses impacting the human, animal and biodefence market. We work in classical BSL2 lab (Herpes, adenovirus, ...), BSL2+ level (influenza H1N1, RSV, rhinovirus) to BSL3 confinement (highly pathogenous influenza, SARS-CoV-2). With our ANCHOR technology, we can directly visualize virus infection and replication in living cells without fixation, extraction or reagents. Customers use our service to identify rapidly and efficiently new antiviral molecules, calibrate disinfection devices, investigate oncolytic virus behavior or understand the biology of gene therapy vectors. Our technologies relies on state off the art microscopy platform, providing our customers qualitative images for communication and marketing operations. If viruses is of your concern, contact us: contact@neovirtech.com More informations: www.neovirtech.com